Dr. Mark Emberton presented “Focal Therapy for Men with Intermediate Risk Prostate Cancer and a Solitary Lesion Should Be the Standard of Care” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.

Keywords: prostate cancer, focal therapy, lesion

How to cite: Emberton, Mark. “Focal Therapy for Men with Intermediate Risk Prostate Cancer and a Solitary Lesion Should Be the Standard of Care” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2019. https://grandroundsinurology.com/focal-therapy-men-intermediate-risk-prostate-cancer-solitary-lesion-standard-care.

This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organised by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.